Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Hanson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Pharmaceutical Design|April 10, 1999
DR (MHC class II) ligands: an approach to rheumatoid arthritis therapeuticsG J Hanson
The Journal of Laboratory and Clinical Medicine|January 19, 2000
First human studies with a high-molecular-weight iron chelatorP R Dragsten, P E Hallaway, G J Hanson, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Renin inhibitor SC-51106 complexed with human renin: discovery of a new binding site adjacent to P3G J Hanson, M Clare, N L Summers, et al.
Biochemical and Biophysical Research Communications|October 15, 1985
Dipeptide glycols: a new class of renin inhibitorsG J Hanson, J S Baran, T Lindberg, et al.
Biochemical and Biophysical Research Communications|August 14, 1987
Enhanced potency dipeptide glycol renin inhibitors: studies in vitro and in the conscious rhesusG J Hanson, J S Baran, H S Lowrie, et al.
Hypertension (Dallas, Tex. : 1979)|July 1, 1995
Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogsE G McMahon, P C Yang, M A Babler, et al.
Biochemical and Biophysical Research Communications|April 14, 1989
A new class of orally active glycol renin inhibitors containing phenyllactic acid at P3G J Hanson, J S Baran, H S Lowrie, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferationS L Woulfe, C P Bono, M L Zacheis, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Pharmaceutical Design|April 10, 1999
DR (MHC class II) ligands: an approach to rheumatoid arthritis therapeuticsG J Hanson
The Journal of Laboratory and Clinical Medicine|January 19, 2000
First human studies with a high-molecular-weight iron chelatorP R Dragsten, P E Hallaway, G J Hanson, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Renin inhibitor SC-51106 complexed with human renin: discovery of a new binding site adjacent to P3G J Hanson, M Clare, N L Summers, et al.
Biochemical and Biophysical Research Communications|October 15, 1985
Dipeptide glycols: a new class of renin inhibitorsG J Hanson, J S Baran, T Lindberg, et al.
Biochemical and Biophysical Research Communications|August 14, 1987
Enhanced potency dipeptide glycol renin inhibitors: studies in vitro and in the conscious rhesusG J Hanson, J S Baran, H S Lowrie, et al.
Hypertension (Dallas, Tex. : 1979)|July 1, 1995
Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogsE G McMahon, P C Yang, M A Babler, et al.
Biochemical and Biophysical Research Communications|April 14, 1989
A new class of orally active glycol renin inhibitors containing phenyllactic acid at P3G J Hanson, J S Baran, H S Lowrie, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferationS L Woulfe, C P Bono, M L Zacheis, et al.
Pageof 1